Biocept Valuation
| BIOCDelisted Stock | USD 1.45 0.17 13.28% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Biocept shows a prevailing Real Value of $1.38 per share. The current price of the firm is $1.45. Our model approximates the value of Biocept from analyzing the firm fundamentals such as Shares Outstanding of 2.63 M, operating margin of (10.38) %, and Return On Equity of -1.87 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Biocept's price fluctuation is very steady at this time. Calculation of the real value of Biocept is based on 3 months time horizon. Increasing Biocept's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Biocept is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Biocept Stock. However, Biocept's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.45 | Real 1.38 | Hype 1.45 | Naive 1.83 |
The real value of Biocept Stock, also known as its intrinsic value, is the underlying worth of Biocept Company, which is reflected in its stock price. It is based on Biocept's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Biocept's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Biocept helps investors to forecast how Biocept stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biocept more accurately as focusing exclusively on Biocept's fundamentals will not take into account other important factors: Biocept Total Value Analysis
Biocept is currently estimated to have valuation of 5.92 M with market capitalization of 1.14 M, debt of 12.11 M, and cash on hands of 27.57 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Biocept fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.92 M | 1.14 M | 12.11 M | 27.57 M |
Biocept Investor Information
The company has price-to-book (P/B) ratio of 0.37. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biocept recorded a loss per share of 48.17. The entity last dividend was issued on the 8th of September 2020. The firm had 1:30 split on the 17th of May 2023. Based on the key indicators related to Biocept's liquidity, profitability, solvency, and operating efficiency, Biocept is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.Biocept Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biocept has an asset utilization ratio of 83.76 percent. This indicates that the Company is making $0.84 for each dollar of assets. An increasing asset utilization means that Biocept is more efficient with each dollar of assets it utilizes for everyday operations.Biocept Ownership Allocation
Biocept shows 9.2 percent of its outstanding shares held by insiders and 1.98 percent owned by other corporate entities.Biocept Profitability Analysis
The company reported the previous year's revenue of 25.86 M. Net Loss for the year was (32.09 M) with loss before overhead, payroll, taxes, and interest of (2.58 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Biocept's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Biocept and how it compares across the competition.
About Biocept Valuation
The delisted stock valuation mechanism determines Biocept's current worth on a weekly basis. Our valuation model uses a comparative analysis of Biocept. We calculate exposure to Biocept's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biocept's related companies.Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell and circulating cell-free tumor DNA and RNA assays utilizing a standard blood sample. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California. Biocept operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 177 people.
Biocept Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 17 M |
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Other Consideration for investing in Biocept Stock
If you are still planning to invest in Biocept check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biocept's history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| CEOs Directory Screen CEOs from public companies around the world | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |